hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06350864 id: FMASU R11/2024 briefTitle: HFNC Versus Conventional Oxygen Therapy in Prolonged Upper Gastrointestinal Endoscopy in the ICU overallStatus: RECRUITING date: 2024-01-20 date: 2024-06 date: 2024-07 date: 2024-04-05 date: 2024-04-05 name: Ain Shams University class: OTHER briefSummary: Conventional supplemental oxygen therapy (COT) during upper gastrointestinal (UGI) endoscopy via nasal catheter is considered the standard practice in maintenance of oxygenation and prevention of hypoxia. However, it is still unclear if this oxygen delivery method is optimal in a prolonged (more than 15 minutes) procedure in patients admitted to the ICU. Because of shortage of data in this concern, this prospective, randomized, controlled clinical trial study will aim to evaluate and compare the efficacy of high-flow nasal cannula (HFNC) oxygen therapy versus COT in patients who will undergo prolonged either diagnostic or therapeutic UGI endoscopy in the intensive care unit (ICU) . conditions: Upper Gastrointestinal Bleeding studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A prospective, randomized, comparative, controlled clinical trial study primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The patients and anesthesiologists in charge of the case will be unmasked as High-flow nasal cannula HFNC) shape,setting and preparation are completely different from the Conventional nasal oxygen therapy (COT), so masking both of them is impossible. whoMasked: INVESTIGATOR count: 70 type: ESTIMATED name: High-flow nasal cannula (HFNC) name: Conventional nasal oxygen therapy (COT) name: Upper gastrointestinal endoscopy (UGE) including gastroscopy name: Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA) measure: Any occurrence of at least moderate hypoxemia of any duration measured by pulse oximetry during the procedure. measure: The median lowest SpO2 -Any episode of hypoxia -Clinically significant hypoxia -Sedation and procedure related adverse effects -Endoscopy procedure time -Anesthetic time -Propofol total used doses measure: Any episode of hypoxia occurring less than 1 minute, from 1 to 5 minutes, or more than 5 minutes measure: Clinically significant hypoxia measure: Sedation related adverse effects (SRAEs) measure: Procedure-related adverse events (PRAEs) measure: Endoscopy procedure time measure: Anesthetic time sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Ain Shams University-Faculty of Medicine status: RECRUITING city: Cairo country: Egypt name: Ahmed M Mohamed, MD role: CONTACT phone: 002 01121318459 email: drahmed.mostafa.mohamed@med.asu.edu.eg name: Wessam Z Selima, MD role: CONTACT phone: 002 01001958858 email: w.z.selima@med.asu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06350851 id: BA161WP1 briefTitle: Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination acronym: Obi1 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-04 date: 2024-04-05 date: 2024-04-05 name: Bioaster class: OTHER briefSummary: Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases. Existing diagnostic tools for onchocerciasis have limitations that make mapping, epidemiological assessments and verification of elimination of onchocerciasis difficult. It is in this context that WHO, in its 2021-2030 roadmap for onchocerciasis, has identified the development of new diagnostic tests, or the improvement of existing diagnostic tests, as a critical condition for achieving the goal of eliminating onchocerciasis transmission.
To this end, a series of cross-sectional studies will be carried out in Cameroun over a one year period to collect and characterize biological samples for the development and evaluation of a new rapid diagnostic test for onchocerciasis. The study will target individuals aged 18 and over, mono-infected with one of the filarial species Onchocerca volvulus, Loa loa or Mansonella perstans; and non-infected.
At the end of this study, data on the endemicity of onchocerciasis, loiasis and mansonellosis in the selected communities will be updated. More importantly, a new rapid diagnostic test will be developed, which can then be used to monitor the activities of onchocerciasis control programs. conditions: Onchocerciasis conditions: Loiasis conditions: Mansonelliasis conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 400 type: ESTIMATED name: Biological samples collection (blood drawing + feces) measure: Evaluation of the performance of the prototype diagnostic test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Higher Institute for Scientific and Medical Research city: Yaounde zip: 5797 country: Cameroon name: Joseph KAMGNO role: CONTACT phone: +237 6 75 06 91 58 email: contact@ismcm.org name: Joseph KAMGNO role: PRINCIPAL_INVESTIGATOR lat: 3.86667 lon: 11.51667 hasResults: False
nctId: NCT06350838 id: KN-BCG-I briefTitle: Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC) overallStatus: COMPLETED date: 2022-11-11 date: 2023-02-13 date: 2023-02-13 date: 2024-04-05 date: 2024-04-05 name: Chengdu CoenBiotech Co., Ltd class: INDUSTRY name: Hunan Cancer Hospital briefSummary: Phase I clinical study to investigate the safety and tolerance of therapeutic BCG in postoperative adjuvant therapy in subjects with moderate to high-risk non-muscular invasive bladder cancer (NMIBC) conditions: Non-muscular Invasive Bladder Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ACTUAL name: BCG for Therapeutic Use measure: Incidence of Treatment-Emergent Adverse Events(TEAE) and serious Treatment-Emergent Adverse Events; measure: Effects on clinical laboratory tests index of blood biochemistry, such as the concentration of alanine aminotransferase (ALT). measure: Effects on clinical laboratory tests index of blood routine, such as white blood cell count, red blood cell count, platelet count. measure: Effects on clinical laboratory tests index of coagulation function, such as activated partial thromboplastin time (APTT). measure: Effects on clinical laboratory tests index of urine routine, such as white urine albumin count, urine red blood cell count. measure: Effects on vital signs,such as temperature. measure: Effects on P wave, QRS complex, QT interval and so on by 12-lead electrocardiogram. measure: Effects on the periodic activity of echocardiography，such as the heart wall recorded as the relationship curve between the corresponding activity and time of each structure. measure: Effects on physical examination, refers to the detection and measurement of the development level of human form, structure and function. measure: Exposure condition of the test drug in the blood, refer to plasma concentration of the test drug(BCG). measure: Shedding condition of the test drug in urine. measure: To investigate the immune response characteristics of therapeutic BCG in patients with moderate and high- risk non-invasive bladder cancer after surgery. sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hunan Cancer Hospital city: Changsha state: Hunan zip: 415000 country: China lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06350825 id: 2023-SR-543 briefTitle: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients overallStatus: RECRUITING date: 2016-01-01 date: 2027-12-31 date: 2028-12-31 date: 2024-04-05 date: 2024-04-05 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP) conditions: Metastatic Prostate Cancer conditions: Therapy, Directly Observed studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized control primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Cytoreductive prostatectomy or brachytherapy name: ADT+second-generation antiandrogens ± chemotherapy measure: rPFS measure: Safety of CRP in mHSPC patients sex: MALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210029 country: China name: Shangqian Wang, M.D. role: CONTACT phone: 13770561625 email: wsq5501@126.com name: Lixin Hua, M.D. role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 typeAbbrev: Prot_ICF hasProtocol: True hasSap: False hasIcf: True label: Study Protocol and Informed Consent Form date: 2024-03-20 uploadDate: 2024-03-20T11:18 filename: Prot_ICF_000.pdf size: 125657 hasResults: False
nctId: NCT06350812 id: PB119110 briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2025-04-29 date: 2025-04-29 date: 2024-04-05 date: 2024-04-05 name: PegBio Co., Ltd. class: OTHER briefSummary: The trial is conducted in a single-center, randomized, double-blind, placebocontrolled, dose-increasing design. To evaluate the safety, tolerability, PK characteristics, efficacy and immunogenicity of PB-119 injection in Chinese obese subjects. conditions: Obesity studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: PB-119 name: Placebo measure: Incidence of Treatment-Emergent Adverse Events measure: Pharmacokinetic profile measure: Pharmacokinetic profile measure: Pharmacokinetic profile measure: Pharmacokinetic profile measure: Effectiveness index measure: Effectiveness index sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06350799 id: 01741 briefTitle: Chronic Obstructive Pulmonary Disease and Community Health Worker Home-visits overallStatus: COMPLETED date: 2019-03-14 date: 2021-05-27 date: 2023-04-28 date: 2024-04-05 date: 2024-04-05 name: VA Puget Sound Health Care System class: FED name: Public Health - Seattle and King County name: University of Washington briefSummary: We examined a Community Health Worker (CHW) program for Chronic Obstructive Pulmonary Disease (COPD) in Veteran Participants. The goal of this study was to assess participants' perceived acceptability, appropriateness, and feasibility of the intervention, explore participants' COPD health outcomes, and gather insights from participants and CHWs to inform potential improvements.
Researchers examined the participant and CHW perception of the intervention through qualitative interviews and surveys. conditions: COPD studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 9 type: ACTUAL measure: Acceptability, Appropriateness, Feasibility sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VA Puget Sound Health Care System city: Seattle state: Washington zip: 98108 country: United States lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06350786 id: ROM Study id: PZ00P1_201972 type: OTHER_GRANT domain: Swiss National Science Foundation briefTitle: Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain acronym: ROM overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-07 date: 2024-04-05 date: 2024-04-05 name: Cosima Locher class: OTHER name: Brown University name: University of Basel briefSummary: This study aims to evaluate whether the reduction of the daily morphine equivalent dose (MED) in patients with chronic non-cancer pain (CNCP) can be decreased with an open-label placebo (OLP) intervention in comparison to an electronic monitoring (EM) control group. The participants will receive the intervention (OPL or EM) over the duration of six weeks. Diverse psychological and health measures will be assessed with questionnaires over the course of the intervention. Furthermore, evaluation outcomes, qualitative outcomes and safety outcomes will be assessed. It is hypothesized that the OLP-intervention group in comparison to the EM-control group will have a significantly lower consumption of MED over the course of the study. Furthermore, this study aims to evaluate whether the OLP intervention can reduce opioid withdrawal symptoms in comparison to the control group. conditions: Chronic Non-cancer Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 86 type: ESTIMATED name: P-Dragees blue Lichtenstein, Placebo dragees name: Control group (EM) measure: Daily opioid consumption (MED): measure: Subjective opioid withdrawal symptoms measure: Pain severity measure: Pain disability measure: Anxiety measure: Depression measure: Pain Opioid Analgesics Beliefs Scale - Cancer measure: Treatment Expectancy measure: Placebo pill count measure: Opioid adherence measure: Rationale credibility measure: Placebo understanding measure: Patient Provider Connection measure: Medication history measure: Primary treating physicians' acceptability of the OLP approach: measure: Primary treating physicians' treatment expectancies measure: Qualitative Outcomes measure: Safety Outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06350773 id: FMBSUREC/06122022/ Zaher briefTitle: Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension overallStatus: RECRUITING date: 2023-01-10 date: 2024-07 date: 2024-11 date: 2024-04-05 date: 2024-04-08 name: Beni-Suef University class: OTHER briefSummary: The goal of this clinical trial is to test the efficacy of tadalafil in patients with group II pulmonary hypertension with elevated pulmonary vascular resistance (PVR). The main question it aims to answer is:
• Can tadalafil improve patients with group II pulmonary hypertension with elevated PVR? Participants will undergo right heart catheterization (RHC) to make sure they are fulfilling the inclusion criteria, then will be asked to take tadalafil 20 mg for two weeks then 40 mg if tolerated for 12 weeks, then participants will be followed up. Investigators will compare the drug group with another age- and sex- matched control placebo group. conditions: Group 2 Pulmonary Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: tadalafil 20 mg then 40 mg if tolerated measure: Functional capacity of the patients measure: heart failure symptoms measure: right ventricular function measure: right ventricular function measure: right ventricular function measure: right ventricular function measure: right ventricular function sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beni Suef University status: RECRUITING city: Cairo state: Beni Suef zip: 62511 country: Egypt name: Hesham Boshra Mahmoud, Doctorate role: CONTACT phone: 201001402250 email: heshamboshra@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06350747 id: CelalBayarU-SBF-OT-02 briefTitle: The Effect of Laughter Yoga on Nurses' Perceived Stress, Sleep Quality, and Burnout Levels overallStatus: RECRUITING date: 2024-04-01 date: 2024-07-01 date: 2024-07-30 date: 2024-04-05 date: 2024-04-18 name: Celal Bayar University class: OTHER briefSummary: The aim of the study was to investigate the effects of laughter yoga on nurses' perceived stress, sleep quality, and burnout levels. conditions: Healthy Participants studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: pretest-posttest with control group primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 64 type: ESTIMATED name: Laughter Yoga measure: Perceived Stress Scale measure: Jenkins Sleep Scale measure: Maslach Burnout Scale sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Manisa Celal Bayar Üniversitesi Hafsa Sultan Hastanesi status: RECRUITING city: Manisa zip: 45060 country: Turkey name: Özge Topsakal, PhD role: CONTACT phone: 05549165599 email: ozgebydr_19@hotmail.com lat: 38.61202 lon: 27.42647 hasResults: False
nctId: NCT06350734 id: 18-004675 id: NCI-2024-00973 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 18-004675 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study overallStatus: RECRUITING date: 2018-10-12 date: 2029-01-31 date: 2029-01-31 date: 2024-04-05 date: 2024-04-05 name: Mayo Clinic class: OTHER briefSummary: This study evaluates the effect of bladder cancer treatment on quality of life. conditions: Stage 0a Bladder Cancer AJCC v8 conditions: Stage 0is Bladder Cancer AJCC v8 conditions: Stage I Bladder Cancer AJCC v8 conditions: Stage II Bladder Cancer AJCC v8 conditions: Stage IIIA Bladder Cancer AJCC v8 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 704 type: ESTIMATED name: Non-Interventional Study measure: Change in quality of life outcomes - PROMIS-29 measure: Change in quality of life outcomes - Bladder Cancer Index measure: Patient level characteristics sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Mark D. Tyson, M.D., M.P.H. role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Paul R. Young, M.D. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Matthew T. Gettman, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06350721 id: DizzyVR briefTitle: Feasibility, Usability and Safety of the Vestibular Rehabilitation Using the Immersive Virtual Reality Software DizzyVR acronym: DizzyVR overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-10-01 date: 2024-04-05 date: 2024-04-05 name: Universidad Loyola Andalucia class: OTHER name: University of Seville name: Universitat Politècnica de València name: Universidad de Zaragoza briefSummary: The goal of this pilot study is to assess the safety and feasibility of the immersive virtual reality system called DizzyVR in participants diagnosed with a vestibular disorder. The main questions it aims to answer are:
Participants will receive the vestibular rehabilitation based on the novel immersive virtual systema, DizzyVR. conditions: Vestibular Disorder conditions: Physical Disability studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 10 type: ESTIMATED name: DizzyVR measure: Retention rate of participants measure: User Satisfaction Evaluation Questionnaire (USEQ) measure: Register of risk and number of adverse events experimented by the stakeholders measure: Adherence rate measure: Dropout rates sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06350708 id: 2024-18304-33663 id: 336664 type: OTHER domain: Integrated Research Application System (IRAS) briefTitle: Virtual Reality (VR) Paediatric Tracheostomy Training overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-07-10 date: 2024-07-10 date: 2024-04-05 date: 2024-04-05 name: University of Manchester class: OTHER briefSummary: This study aims to evaluate the use of an unsupervised virtual reality training tool. This tool is used to teach nurses, doctors and other healthcare workers and their students how to manage tracheostomy emergencies in children. conditions: Educational Study studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 69 type: ESTIMATED name: Virtual reality (VR) tracheostomy educational tool measure: Performance in simulation (time to key specific intervention, time to completion of scenario, and number of correct interventions completed) measure: Knowledge using a bespoke knowledge multiple choice questionnaire adapted from a validated question bank. measure: Participant satisfaction measured using a bespoke data collection tool. measure: Virtual Reality Sickness measure: Usability using the validated system usability scale sex: ALL minimumAge: 18 Years maximumAge: 68 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Manchester city: Manchester state: Greater Manchester zip: M13 9PL country: United Kingdom name: Jonathan R Abbas, MBChB role: CONTACT email: jonathan.abbas@postgrad.manchester.ac.uk lat: 53.48095 lon: -2.23743 hasResults: False
nctId: NCT06350682 id: HP-00107323 briefTitle: Resilient HIV Implementation Science With SGM Youths Using Evidence acronym: RISE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-09 date: 2028-06 date: 2024-04-05 date: 2024-04-05 name: University of Maryland, Baltimore class: OTHER name: University of Florida briefSummary: The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a youth-tailored digital health platform. It is hypothesized that SGM youths in the HMP intervention group will demonstrate improved PrEP initiation and viral load suppression over 12 months compared to the delayed HMP group. conditions: Hiv studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 1500 type: ESTIMATED name: HealthMPowerment (HMP) measure: PrEP initiation for HIV seronegative seropositive measure: Viral load suppression for HIV measure: RE-AIM measure: HIV testing cascade measure: PrEP continuum measure: HIV care and treatment continuum measure: Implementation effectiveness sex: MALE minimumAge: 15 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT hasResults: False